202 related articles for article (PubMed ID: 28358217)
1. Influence of route of administration/drug formulation and other factors on adherence to treatment in rheumatoid arthritis (pain related) and dyslipidemia (non-pain related).
Fautrel B; Balsa A; Van Riel P; Casillas M; Capron JP; Cueille C; de la Torre I
Curr Med Res Opin; 2017 Jul; 33(7):1231-1246. PubMed ID: 28358217
[TBL] [Abstract][Full Text] [Related]
2. Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence Among Texas Medicaid Recipients With Rheumatoid Arthritis.
Kim G; Barner JC; Rascati K; Richards K
Clin Ther; 2016 Mar; 38(3):646-54. PubMed ID: 26899313
[TBL] [Abstract][Full Text] [Related]
3. Medication adherence and cost-related medication non-adherence in patients with rheumatoid arthritis: A cross-sectional study.
Heidari P; Cross W; Weller C; Nazarinia M; Crawford K
Int J Rheum Dis; 2019 Apr; 22(4):555-566. PubMed ID: 30924291
[TBL] [Abstract][Full Text] [Related]
4. Measurement and rates of persistence with and adherence to biologics for rheumatoid arthritis: a systematic review.
Blum MA; Koo D; Doshi JA
Clin Ther; 2011 Jul; 33(7):901-13. PubMed ID: 21715007
[TBL] [Abstract][Full Text] [Related]
5. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
6. Do out-of-pocket costs affect medication adherence in adults with rheumatoid arthritis? A systematic review.
Heidari P; Cross W; Crawford K
Semin Arthritis Rheum; 2018 Aug; 48(1):12-21. PubMed ID: 29496225
[TBL] [Abstract][Full Text] [Related]
7. Adherence and Persistence with Methotrexate in Rheumatoid Arthritis: A Systematic Review.
Curtis JR; Bykerk VP; Aassi M; Schiff M
J Rheumatol; 2016 Nov; 43(11):1997-2009. PubMed ID: 27803341
[TBL] [Abstract][Full Text] [Related]
8. Analysis of drug and administrative costs allowed by U.S. Private and public third-party payers for 3 intravenous biologic agents for rheumatoid arthritis.
Wong BJ; Cifaldi MA; Roy S; Skonieczny DC; Stavrakas S
J Manag Care Pharm; 2011 May; 17(4):313-20. PubMed ID: 21534642
[TBL] [Abstract][Full Text] [Related]
9. Do statins reduce the cardiovascular risk in patients with rheumatoid arthritis?
Danninger K; Hoppe UC; Pieringer H
Int J Rheum Dis; 2014 Jul; 17(6):606-11. PubMed ID: 24931356
[TBL] [Abstract][Full Text] [Related]
10. Cost per patient-year in response using a claims-based algorithm for the 2 years following biologic initiation in patients with rheumatoid arthritis.
Bonafede M; Johnson BH; Princic N; Shah N; Harrison DJ
J Med Econ; 2015 May; 18(5):376-89. PubMed ID: 25530318
[TBL] [Abstract][Full Text] [Related]
11. Non-adherence to subcutaneous biological medication in patients with rheumatoid arthritis: a multicentre, non-interventional study.
Calvo-Alén J; Monteagudo I; Salvador G; Vázquez-Rodríguez TR; Tovar-Beltrán JV; Vela P; Maceiras F; Bustabad S; Román-Ivorra JA; Díaz-Miguel C; Rosas J; Raya E; Carmona L; Cea-Calvo L; Arteaga MJ; Fernández S; Marras C
Clin Exp Rheumatol; 2017; 35(3):423-430. PubMed ID: 28032846
[TBL] [Abstract][Full Text] [Related]
12. Impact of poor medication adherence on clinical outcomes and health resource utilization in patients with hypertension and/or dyslipidemia: systematic review.
Kengne AP; Brière JB; Zhu L; Li J; Bhatia MK; Atanasov P; Khan ZM
Expert Rev Pharmacoecon Outcomes Res; 2024 Jan; 24(1):143-154. PubMed ID: 37862440
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and drug adherence of biologic monotherapy in routine care of patients with rheumatoid arthritis: a cohort study of patients registered in the Danish biologics registry.
Jørgensen TS; Kristensen LE; Christensen R; Bliddal H; Lorenzen T; Hansen MS; Østergaard M; Jensen J; Zanjani L; Laursen T; Butt S; Dam MY; Lindegaard HM; Espesen J; Hendricks O; Kumar P; Kincses A; Larsen LH; Andersen M; Næser EK; Jensen DV; Grydehøj J; Unger B; Dufour N; Sørensen V; Vildhøj S; Hansen IM; Raun J; Krogh NS; Hetland ML
Rheumatology (Oxford); 2015 Dec; 54(12):2156-65. PubMed ID: 26175471
[TBL] [Abstract][Full Text] [Related]
14. Costs associated with failure to respond to treatment among patients with rheumatoid arthritis initiating TNFi therapy: a retrospective claims analysis.
Grabner M; Boytsov NN; Huang Q; Zhang X; Yan T; Curtis JR
Arthritis Res Ther; 2017 May; 19(1):92. PubMed ID: 28506320
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation, persistence and adherence to subcutaneous biologics delivered via a homecare route to Scottish adults with rheumatic diseases: a retrospective study.
Alvarez-Madrazo S; Kavanagh K; Siebert S; Semple Y; Godman B; Maciel Almeida A; Acurcio FA; Bennie M
BMJ Open; 2019 Sep; 9(9):e027059. PubMed ID: 31488467
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms.
Cipriani P; Ruscitti P; Carubbi F; Liakouli V; Giacomelli R
Clin Ther; 2014 Mar; 36(3):427-35. PubMed ID: 24612941
[TBL] [Abstract][Full Text] [Related]
17. Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence.
Dalén J; Svedbom A; Black CM; Lyu R; Ding Q; Sajjan S; Sazonov V; Kachroo S
Rheumatol Int; 2016 Jul; 36(7):987-95. PubMed ID: 26780533
[TBL] [Abstract][Full Text] [Related]
18. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
Chastek B; Chen CI; Proudfoot C; Shinde S; Kuznik A; Wei W
Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
[TBL] [Abstract][Full Text] [Related]
19. Disease activity trajectories in early rheumatoid arthritis following intensive DMARD therapy over 3 years: association with persistence to therapy.
Wabe N; Wojciechowski J; Wechalekar MD; Cleland LG; McWilliams L; Lee A; Proudman S; Wiese MD
Int J Rheum Dis; 2017 Oct; 20(10):1447-1456. PubMed ID: 28952204
[TBL] [Abstract][Full Text] [Related]
20. Identification of patients at risk of non-adherence to oral antirheumatic drugs in rheumatoid arthritis using the Compliance Questionnaire in Rheumatology: an ARCO sub-study.
Marras C; Monteagudo I; Salvador G; de Toro FJ; Escudero A; Alegre-Sancho JJ; Raya E; Ortiz A; Carmona L; Mestre Y; Cea-Calvo L; Calvo-Alén J
Rheumatol Int; 2017 Jul; 37(7):1195-1202. PubMed ID: 28516236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
